rare disease

decentralized clinical trial hybrid clinical trial

COVID-19 and the Changing Landscape of Clinical Trials

 Featured in Applied Clinical Trials: Decentralized trials are the way of the future—yet it would be ill-advised to think of them as a one-size-fits-all solution. While the pandemic increased the industry’s acceptance of decentralized clinical trial protocols, moving to an entirely virtual model without in-person interaction is unrealistic. This sort of hybrid approach allows researchers

COVID-19 and the Changing Landscape of Clinical Trials Read More »

Break barriers to clinical trial participation

Reducing Barriers to Participation in Clinical Trials for Rare Disease

Research teams who appreciate the unique needs of rare disease patients and invest in a white-glove approach on behalf of trial participants can reduce barriers to participation. For sponsors, clinical study teams, and site staff, this means easier patient recruitment at the beginning of a study and fewer dropouts throughout the duration of the trial—with

Reducing Barriers to Participation in Clinical Trials for Rare Disease Read More »

error: Protected content.